SMURF2 and breast carcinoma: As SMURF2 is a potent inhibitor of TGF-β activity we investigated whether introducing a K734R mutant of SMURF2 into the TGF-β responsive metastatic breast cancer cell line MDA-MB-231 compromises the ability of SMURF2 to reduce TGF-β dependent migration.